“Generic AI tools struggle with ABL due to limited training data and lack of domain context,” said John Ainsworth, EVP and General Manager, Application and Data Platform, Progress Software. “The ...
Immunovant, Inc. reported significant progress related to its lead asset IMVT-1402, having secured six Investigational New Drug applications and currently enrolling participants in pivotal studies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results